Education
About Us
Working with TipRanks
Follow Us
Xeris Pharmaceuticals (XERS)
:XERS
| Dec 24 | Dec 23 | Dec 23 | Dec 23 | Dec 23 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 203.07M | $ 163.91M | $ 163.91M | $ 163.91M | $ 163.91M |
| Gross Profit | $ 166.24M | $ 135.27M | $ 135.27M | $ 135.27M | $ 135.27M |
| Operating Income | $ -33.65M | $ -44.01M | $ -44.01M | $ -44.01M | $ -44.01M |
| EBITDA | $ -11.30M | $ -23.73M | $ -23.73M | $ -23.73M | $ -23.73M |
| Net Income | $ -54.84M | $ -62.26M | $ -62.26M | $ -62.26M | $ -62.26M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 71.62M | $ 72.45M | $ 72.45M | $ 72.45M | $ 72.45M |
| Total Assets | $ 323.06M | $ 322.60M | $ 322.60M | $ 322.60M | $ 322.60M |
| Total Debt | $ 271.45M | $ 229.19M | $ 229.19M | $ 229.19M | $ 229.19M |
| Net Debt | $ 199.83M | $ 161.74M | $ 161.74M | $ 161.74M | $ 161.74M |
| Total Liabilities | $ 352.68M | $ 329.38M | $ 329.38M | $ 329.38M | $ 329.38M |
| Stockholders' Equity | $ -29.61M | $ -6.78M | $ -6.78M | $ -6.78M | $ -6.78M |
| Cash Flow | |||||
| Free Cash Flow | $ -37.85M | $ -49.29M | $ -49.29M | $ -49.29M | $ -49.29M |
| Operating Cash Flow | $ -36.98M | $ -47.02M | $ -47.02M | $ -47.02M | $ -47.02M |
| Investing Cash Flow | $ 4.88M | $ -6.00M | $ -6.00M | $ -6.00M | $ -6.00M |
| Financing Cash Flow | $ 36.17M | $ -1.61M | $ -1.61M | $ -1.61M | $ -1.61M |